In the phase 3 ALCYONE trial of patients with transplant-ineligible, newly diagnosed multiple myeloma, the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) continues to demonstrate a significant progression-free survival (PFS) benefit, in addition to a prolonged overall survival (OS) benefit, when compared with bortezomib, melphalan, and prednisone (VMP) alone.
Now, after a median follow-up of 40.1 months, updated survival data reveal a median PFS of 36.4 months with D-VMP versus 19.3 months with VMP (P <.0001; hazard ratio, 0.42). The estimated 42-month OS rate was 75% with D-VMP versus 62% with VMP, with a significant benefit for OS observed for D-VMP versus VMP alone (P = .0003). Median OS was not reached in either group and follow-up is ongoing.
“For the first time, we demonstrate that the addition of daratumumab to bortezomib, melphalan, and prednisone prolongs overall survival in patients with transplant-ineligible newly diagnosed multiple myeloma, with a 40% reduction in the risk of death versus [bortezomib, melphalan, and prednisone] alone, after a median follow-up of 40 months,” said presenting author Maria-Victoria Mateos, from University Hospital of Salamanca/IBSAL, in Salamanca, Spain.
As previously reported, after a median follow-up of almost 30 months, D-VMP reduced the risk of disease progression or death by 57% versus VMP alone, with a 24-month PFS rate of 63% in the D-VMP group and 36% in the VMP group. This PFS benefit was observed regardless of patient age and was maintained during the subsequent line of therapy in these patients.
Together with the phase 3 MAIA study, which established the benefit of adding daratumumab to lenalidomide and dexamethasone, these findings continue to support the addition of daratumumab to frontline treatment regimens in patients with transplant-ineligible, newly diagnosed multiple myeloma.
Daratumumab is a human, CD38-targeting, IgG1κ monoclonal antibody with direct antitumor effects and an immunomodulatory component that has recently led to survival improvements in patients with multiple myeloma when added to standard-of-care regimens. These data confirm the OS benefit of adding daratumumab to standard of care in newly diagnosed, transplant-ineligible patients.
In the trial, 706 patients from 25 countries with newly diagnosed multiple myeloma who were ineligible for high-dose chemotherapy and autologous stem-cell transplantation due to age (≥65 years) or comorbidities were randomized 1:1 to either D-VMP (N = 350) or VMP (N = 356). The median age was 71 years, approximately 30% of patients were over 75 years of age, and the majority of patients had an Eastern Cooperative Oncology Group performance status of 0-1. Patients in the D-VMP and VMP arms, respectively, were International Staging System stage I (20%, 19%), stage II (40%, 45%), and stage III (41%, 36%), and classified as having high cytogenetic risk (17%, 15%).
Overall response rates at primary and updated analysis with D-VMP versus VMP did not change, and remained at 91% and 74%, respectively. However, the quality of responses deepened over time with longer follow-up, with 46% of patients achieving complete response at 40 months, compared with 43% at 16.5 months.
Patients who received D-VMP also had significantly higher rates of minimal residual disease (MRD)-negativity: 28% versus 7% at the time of updated analysis. Regardless of treatment arm, MRD-negative patients saw significantly improved PFS and OS. “However, when we evaluated the proportion of patients who achieved MRD-negativity, at the primary as well as at the updated analysis, D-VMP was always superior to VMP,” she said. MRD-negativity was also more sustained with D-VMP, with 14% of patients still MRD-negative at 1 year, compared with 3% in the VMP arm.
At the clinical cutoff date of June 24, 2019, all patients had either discontinued or completed 9 treatment cycles of VMP, but 146 (42%) patients in the D-VMP group continue to receive daratumumab monotherapy in cycle 10 and beyond (38% of D-VMP patients have discontinued study treatment, mainly due to progressive disease).
Median time to subsequent therapy was not reached for the D-VMP group, and was 25.9 months for the VMP group. No new safety concerns were identified, and rates of discontinuation due to treatment-related adverse events were 6.9% and 9.3% in the D-VMP and VMP arms, respectively.
“This first report of an OS benefit with daratumumab continues to support the use of daratumumab-containing regimens for the treatment of patients with multiple myeloma,” Dr Mateos concluded.
Mateos M, et al. ASH Abstract 859.
To sign up for our newsletter or print publications, please enter your contact information below.
